141 related articles for article (PubMed ID: 14624273)
1. Therapeutics, drug pricing and innovation.
Somberg J
Am J Ther; 2003; 10(6):381. PubMed ID: 14624273
[No Abstract] [Full Text] [Related]
2. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
[TBL] [Abstract][Full Text] [Related]
3. FDA approvals of old drugs put new pressure on payers.
Silverman E
Manag Care; 2011 May; 20(5):30-1. PubMed ID: 21667624
[No Abstract] [Full Text] [Related]
4. The Canadian Cardiovascular Society and reference-based drug pricing.
Olley PM; McLaughlin PR
Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
[No Abstract] [Full Text] [Related]
5. Controlling spending for prescription drugs.
Altman SH; Parks-Thomas C
N Engl J Med; 2002 Mar; 346(11):855-6. PubMed ID: 11893800
[No Abstract] [Full Text] [Related]
6. Holding down prescription drug costs.
FDA Consum; 1975 Dec-1976 Jan; 9(10):9-10. PubMed ID: 10305011
[No Abstract] [Full Text] [Related]
7. No rational theory for drug pricing.
Cox MC; Figg WD; Thurman PW
J Clin Oncol; 2004 Mar; 22(5):962-3. PubMed ID: 14990657
[No Abstract] [Full Text] [Related]
8. Reference-based pricing (RBP) of prescription drugs.
Holbrook A; O'Brien B; Grootendorst P
Can J Cardiol; 1997 Jul; 13(7):689-90. PubMed ID: 9251582
[No Abstract] [Full Text] [Related]
9. The Multi-Billion Dollar Drug-Sensitive Spending Opportunity.
Easter JC; Thorpe K
N C Med J; 2018; 79(1):46-50. PubMed ID: 29439105
[TBL] [Abstract][Full Text] [Related]
10. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
11. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
Augurzky B; Göhlmann S; Gress S; Wasem J
Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
[TBL] [Abstract][Full Text] [Related]
12. Gift giving.
Raszkowski RR
S D J Med; 2002 Dec; 55(12):513-4. PubMed ID: 12516357
[No Abstract] [Full Text] [Related]
13. Increasing use of new prescription drugs: a case study.
Foote SM; Etheredge L
Health Aff (Millwood); 2000; 19(4):165-70. PubMed ID: 10916970
[No Abstract] [Full Text] [Related]
14. The prescription-drug problem.
Steinbrook R
N Engl J Med; 2002 Mar; 346(11):790. PubMed ID: 11893789
[No Abstract] [Full Text] [Related]
15. Medicare and the politics of prescription drug pricing.
Oberlander J
N C Med J; 2003; 64(6):303-4. PubMed ID: 14983626
[No Abstract] [Full Text] [Related]
16. Oncology drug pricing structure is broken.
Hutchinson L
Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
[No Abstract] [Full Text] [Related]
17. Shifting gears.
Tweed V
Bus Health; 1994 May; 12(5):28-9, 32, 34 passim. PubMed ID: 10134334
[No Abstract] [Full Text] [Related]
18. Value-Based Pricing for Drugs: Theme and Variations.
Kaltenboeck A; Bach PB
JAMA; 2018 Jun; 319(21):2165-2166. PubMed ID: 29710320
[No Abstract] [Full Text] [Related]
19. Value-Based Pricing and Patient Access for Specialty Drugs.
Robinson JC; Howell S; Pearson SD
JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
[No Abstract] [Full Text] [Related]
20. Prescription drug pricing: the consumer perspective.
Searing A
N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
